Top

BMC Complementary Medicine and Therapies

Published in:

01-12-2021 | Ulcerative Colitis | Research

Effect of the standard herbal preparation, STW5, treatment on dysbiosis induced by dextran sodium sulfate in experimental colitis

Authors: Sarah S. Mohamed, Nourtan F. Abdeltawab, Walaa Wadie, Lamiaa A. Ahmed, Ramy M. Ammar, Sabine Rabini, Heba Abdel-Aziz, Mohamed T. Khayyal

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

The standardized herbal preparation, STW 5, is effective clinically in functional gastrointestinal disorders and experimentally in ulcerative colitis (UC). The present study explores whether the beneficial effect of STW 5 involves influencing the intestinal microbiota.

Methods

UC was induced in Wistar rats by feeding them 5% dextran sodium sulfate (DSS) in drinking water for 7 days. Rats were treated concurrently with STW 5 and sacrificed 24 h after last drug administration. Fecal samples were used to determine changes in the abundance of selected microbial phyla and genera using real-time PCR.

Results

Induction of UC led to dysbiosis and changes in the gut microbiota. The changes included an increase in some genera of the Firmicutes, namely Enterococcus, and a decrease in others, namely Blautia, Clostridium, and Lactobacillus. DSS further induced a marked increase in the abundance of Bacteroidetes and Proteobacteria as well as in the relative abundance of Actinobacteria and its genus Bifidobacterium. Methanobrevibacter levels (phylum Euryarchaeota) were also increased. Microbial dysbiosis was associated with changes in various parameters of colonic inflammation. STW 5 effectively guarded against those changes and significantly affected the indices of edema and inflammation in the UC model. Changes in colon length, colon mass index, inflammatory and apoptotic markers, and histological changes induced by DSS were also prevented.

Conclusions

Dysbiosis plays a contributing role in the development of DSS-induced UC. Derangements in the microbial flora and associated inflammatory processes were largely prevented by STW 5, suggesting that this effect might contribute towards its beneficial usefulness in this condition.

Available only for authorised users

M'koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33–47. https://doi.org/10.4137/CGast.S12731.CrossRefPubMedPubMedCentral

Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9. https://doi.org/10.3748/wjg.v20.i1.91.CrossRefPubMedPubMedCentral

H. Laroui, S. A. Ingersoll, H. C. Liu, , M. T. Baker, S. Ayyadurai, M. A. Charania, F. Laroui, Y. Yan, S.V. Sitaraman, D. Merlin, Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon, PLoS One (2012), 7, e32084, 3, doi: https://doi.org/10.1371/journal.pone.0032084.CrossRefPubMedPubMedCentral

Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol.Ther. 2015;149:191–212. https://doi.org/10.1016/j.pharmthera.2014.12.006.CrossRefPubMed

Du Z, Hudcovic T, Mrazek J, Kozakova H, Srutkova D, Schwarzer M, et al. Development of gut inflammation in mice colonized with mucosa-associated bacteria from patients with ulcerative colitis. Gut Pathog. 2015;7(1):32. https://doi.org/10.1186/s13099-015-0080-2.CrossRefPubMedPubMedCentral

Tannock G. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol. 2008;1(S1):S15–8. https://doi.org/10.1038/mi.2008.54.CrossRefPubMed

Munyaka PM, Rabbi MF, Khafipour E, Ghia JE. Acute dextran sulfate sodium (DSS)-induced colitis promotes gut microbial dysbiosis in mice. J Basic Microbiol. 2016;56(9):986–98. https://doi.org/10.1002/jobm.201500726.CrossRefPubMed

Stanghellini V, Chan KL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380–92. https://doi.org/10.1053/j.gastro.2016.02.011.CrossRefPubMed

Quigley EM. Bugs on the brain; brain in the gut--seeking explanations for common gastrointestinal symptoms. Ir J Med Sci. 2013;182:1–6.CrossRefPubMed

10.

Shin A, Preidis GA, Shulman R, Kashyap PC. The gut microbiome in adult and pediatric functional gastrointestinal disorders. Clin Gastroenterol Hepatol. 2019;17:256–74.CrossRefPubMed

11.

Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111–23. https://doi.org/10.1053/j.gastro.2016.09.049.CrossRefPubMed

12.

Hold GL, Pryde SE, Russell VJ, Furrie E, Flint HJ. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol Ecol. 2002;39(1):33–9. https://doi.org/10.1111/j.1574-6941.2002.tb00904.x.CrossRefPubMed

13.

Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14. https://doi.org/10.1038/nature11234.CrossRef

14.

Collins SM. A role for the gut microbiota in IBS. Nat RevGastroenterol Hepatol. 2014;11(8):497–505. https://doi.org/10.1038/nrgastro.2014.40.CrossRef

15.

Allescher HD, Wagner H. STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome. Wien. Med. Wochenschr. 2007;157(13-14):301–7. https://doi.org/10.1007/s10354-007-0429-3.CrossRefPubMed

16.

Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013;16:65–72.CrossRef

17.

Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine. 2006;13:12–9. https://doi.org/10.1016/j.phymed.2006.03.016.CrossRefPubMed

18.

Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine. 2006;13:20–35. https://doi.org/10.1016/j.phymed.2006.07.001.CrossRefPubMed

19.

Wadie W, Abdel-Aziz H, Zaki HF, Kelber O, Weiser D, Khayyal MT. STW 5 is effective in dextran sulfate sodium-induced colitis in rats. IntJ Colorectal Dis. 2012;27(11):1445–53. https://doi.org/10.1007/s00384-012-1473-z.CrossRef

20.

Viennois E, Chen F, Laroui H, Baker MT, Merlin D. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC ResNotes. 2013;6:360.

21.

Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol. 2008;47(5):367–73. https://doi.org/10.1111/j.1472-765X.2008.02408.x.CrossRefPubMed

22.

Delroisse JM, Boulvin AL, Parmentier I, Dauphin RD, Vandenbol M, Portetelle D. Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time. PCR Res. 2008;163:663–70.

23.

Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol. 2004;70(12):7220–8. https://doi.org/10.1128/AEM.70.12.7220-7228.2004.CrossRefPubMedPubMedCentral

24.

Rinttilä T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004;97(6):1166–77. https://doi.org/10.1111/j.1365-2672.2004.02409.x.CrossRefPubMed

25.

Bekele AZ, Koike S, Kobayashi Y. Genetic diversity and diet specificity of ruminal Prevotella revealed by 16S rRNA gene-based analysis. FEMS Microbiol Lett. 2010;30:49–57.CrossRef

26.

Stach JEM, Maldonado LA, Ward AC, Goodfellow M, Bull AT. New primers for the class Actinobacteria: application to marine and terrestrial environments. Environ Microbiol. 2003;5(10):828–41. https://doi.org/10.1046/j.1462-2920.2003.00483.x.CrossRefPubMed

27.

Friswell MK, Gika H, Stratford IJ, Theodoridis G, Telfer B, Wilson ID, et al. Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice. PLoS One. 2010;5(1):e8584. https://doi.org/10.1371/journal.pone.0008584.CrossRefPubMedPubMedCentral

28.

Dridi B, Henry M, El Khéchine A, Raoult D, Drancourt M. High prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae detected in the human gut using an improved DNA detection protocol. PLoS One. 2009;4(9):e7063. https://doi.org/10.1371/journal.pone.0007063.CrossRefPubMedPubMedCentral

29.

Reinisch W. Fecal microbiota transplantation in inflammatory bowel disease. Dig Dis. 2017;35(1-2):123–6. https://doi.org/10.1159/000449092.CrossRefPubMed

30.

Hansen J, Gulati A, Sartor RB. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr Opin Gastroenterol. 2010;26(6):564–71. https://doi.org/10.1097/MOG.0b013e32833f1195.CrossRefPubMedPubMedCentral

31.

Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002;17(8):849–53. https://doi.org/10.1046/j.1440-1746.2002.02834.x.CrossRefPubMed

32.

Scanlan PD, Shanahan F, Marchesi JR. Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol. 2008;8(1):79. https://doi.org/10.1186/1471-2180-8-79.CrossRefPubMedPubMedCentral

33.

Ghavami SB, Rostami E, Sephay AA, Shahrokh S, Balaii H, Aghdaei HA, et al. Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases. Microb Pathog. 2018;117:285–9. https://doi.org/10.1016/j.micpath.2018.01.029.CrossRefPubMed

34.

Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett. 2002;217(2):133–9. https://doi.org/10.1111/j.1574-6968.2002.tb11467.x.CrossRefPubMed

35.

Segain JP, Raingeard de la Blétiere D, Bourreille A, Leray V, Gervois N, Rosales C, et al. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut. 2000;47(3):397–403. https://doi.org/10.1136/gut.47.3.397.CrossRefPubMedPubMedCentral

36.

Slover CM, Danziger L. Lactobacillus: a review. Clin Microbiol Newsl. 2008;30(4):23–7. https://doi.org/10.1016/j.clinmicnews.2008.01.006.CrossRef

37.

Fabia R, Ar’Rajab A, Johansson ML, Andersson R, Willén R, Jeppsson B, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 1993;54(4):248–55. https://doi.org/10.1159/000201045.CrossRefPubMed

38.

Ott SJ, Plamondon S, Hart A, Begun A, Rehman A, Kamm MA, et al. Dynamics of the mucosa-associated flora in ulcerative colitis patients during remission and clinical relapse. J Clin Microbiol. 2008;46(10):3510–3. https://doi.org/10.1128/JCM.01512-08.CrossRefPubMedPubMedCentral

39.

Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151(4):363–74. https://doi.org/10.1111/imm.12760.CrossRefPubMedPubMedCentral

40.

Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, et al. Increased proportion of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clini Microbiol. 2014;52(2):398–406. https://doi.org/10.1128/JCM.01500-13.CrossRef

41.

Pimentel M, Lin HC, Enayati P, van den Burg B, Lee HR, Chen JH, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290:1089–95.CrossRef

42.

Kim G, Deepinder F, Morales W, Hwang L, Weitsman S, Chang C, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath. Dig Dis Sci. 2012;57(12):3213–8. https://doi.org/10.1007/s10620-012-2197-1.CrossRefPubMed

43.

Maharshak N, Packey CD, Ellermann M, Manick S, Siddle JP, Huh EY, et al. Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation. Gut Microbes. 2013;4(4):316–24. https://doi.org/10.4161/gmic.25486.CrossRefPubMedPubMedCentral

44.

Selvanantham T, Lin Q, Guo CX, Surendra A, Fieve S, Escalante NK, et al. NKT cell–deficient mice harbor an altered microbiota that fuels intestinal inflammation during chemically induced colitis. J Immunol. 2016;197(11):4464–72. https://doi.org/10.4049/jimmunol.1601410.CrossRefPubMed

45.

Cuiv PE, De Wouters T, Giri R, Mondot S, Smith WJ, Blottiere HM, et al. The gut bacterium and pathobiont Bacteroides vulgatus activates NF-κB in a human gut epithelial cell line in a strain and growth phase dependent manner. Anaerobe. 2017;47:209–17. https://doi.org/10.1016/j.anaerobe.2017.06.002.CrossRef

46.

Philippe D, Heupel E, Blum-Sperisen S, Riedel CU. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int J Food Microbiol. 2011;149(1):45–9. https://doi.org/10.1016/j.ijfoodmicro.2010.12.020.CrossRefPubMed

47.

Khayyal MT, El-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung. 2001;51(7):545–53. https://doi.org/10.1055/s-0031-1300078.CrossRefPubMed

48.

Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine. 2006;13(Suppl 5):56–66.CrossRefPubMed

49.

Abdel-Aziz H, Wadie W, Zaki HF, Müller J, Kelber O, Efferth T, et al. Novel sequential stress model for functional dyspepsia: Efficacy of the herbal preparation STW5. Phytomedicine. 2015;22(5):588–95.CrossRefPubMed

Title: Effect of the standard herbal preparation, STW5, treatment on dysbiosis induced by dextran sodium sulfate in experimental colitis
Authors: Sarah S. Mohamed
Nourtan F. Abdeltawab
Walaa Wadie
Lamiaa A. Ahmed
Ramy M. Ammar
Sabine Rabini
Heba Abdel-Aziz
Mohamed T. Khayyal
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ulcerative Colitis
Clostridium
Respiratory Microbiota
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03337-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of the standard herbal preparation, STW5, treatment on dysbiosis induced by dextran sodium sulfate in experimental colitis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials

Headache and migraine clinical practice guidelines: a systematic review and assessment of complementary and alternative medicine recommendations

Exploring the bone sparing effects of postbiotics in the post-menopausal rat model

Lippia javanica (Zumbani) herbal tea infusion attenuates allergic airway inflammation via inhibition of Th2 cell activation and suppression of oxidative stress

Anti-inflammatory effect of different curcumin preparations on adjuvant-induced arthritis in rats

Suppression of autophagy through JAK2/STAT3 contributes to the therapeutic action of rhynchophylline on asthma